The Asia Pacific mycoplasma testing market was worth USD 118.12 Million in 2018 and is estimated to be growing at a CAGR of 16.7%, to reach USD 255.67 Million by 2023. Mycoplasma are the simplest and smallest microorganisms till date and they are self-replicating too. They do not possess a complete set of genetic material and hence they cannot conduct certain functions such as synthesis of amino acids and cell wall generation.
The cells contaminated by mycoplasma go unnoticed most of the time. They do not cause observable changes after contamination in a cell culture such as change in turbidity and pH. Also, due to their small size they cannot be detected by a light microscope. However, they showcase virulent effects on eukaryotic cells such as altering protein synthesis, cellular metabolism etc. Hence, mycoplasma testing has become essential in cell culture research laboratories.
Increasing investments for life sciences research, rising number of pharma and biotech industries due to the increase in government funding for R&D in drug development and new technological advancements in mycoplasma testing methods are expected to propel the market in the given forecast period. However, factors such as inflexible government regulations and excessive costs involved with mycoplasma testing methods are inhibiting the growth of the market.
The Asia-Pacific mycoplasma testing market is segmented on the basis of product, technique, application, end user and region. On the basis of product, the market is segmented into kits & reagents, instruments and services. Kits & reagent is expected to hold the largest market share in this segment. This is due to the requirement for repeated purchase of these products as they are consumed with each test while instruments need not be purchased frequently. Based on technique, the market is segmented into PCR, ELSA, Direct Assays, Indirect Assays, Microbial culture techniques, Enzymatic Methods, and DNA Staining. PCR technique is projected to lead the market in this segment as it is highly accepted in life sciences research due to the speed and flexibility of this technique. Based on application, the mycoplasma testing market is segmented into Cell Line Testing, Virus Testing, End-Of-Production Cell Testing and other applications. Cell line testing is expected to lead the market and is also one of the rapidly growing segments due to the increasing application of cell line testing in research as well as biopharmaceutical production. Based on end user, the market is segmented into Pharmaceutical Companies, Contract research organizations, Academic Research Institutes and Cell Banks. Pharmaceutical companies segment holds the largest market share due to the increasing R&D activities in pharmaceutical and biotechnology companies.
The mycoplasma testing market in Asia-Pacific is segmented into China, India, Japan, Australia and South Korea based on the region. Asia-Pacific is the fastest growing market for mycoplasma testing due to the increase in number of pharmaceutical and biotechnology industries and thriving trend of pharmaceutical outsourcing to this region.
Major companies in the mycoplasma testing market include PromoCell GmbH, Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Lonza Group Ltd., Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, Biological Industries Israel Beit Haemek Ltd., and WuXi AppTec.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Kits & Reagent
5.1.3 Instruments
5.1.4 Services
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Technique
5.2.1 Introduction
5.2.2 PCR
5.2.3 ELSA
5.2.4 Direct Assays
5.2.5 Indirect Assays
5.2.6 Microbial culture techniques
5.2.7 Enzymatic Methods
5.2.8 DNA Staining
5.2.9 Y-o-Y Growth Analysis, By Technique
5.2.10 Market Attractiveness Analysis, By Technique
5.2.11 Market Share Analysis, By Technique
5.3 Application
5.3.1 Introduction
5.3.2 Cell Line Testing
5.3.3 Virus Testing
5.3.4 End-Of-Production Cell Testing
5.3.5 Other Applications
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End User
5.4.1 Introduction
5.4.2 Pharmaceutical Companies
5.4.3 Contract Research Organizations
5.4.4 Academic Research Institutes
5.4.5 Cell Banks
5.4.6 Y-o-Y Growth Analysis, By End User
5.4.7 Market Attractiveness Analysis, By End User
5.4.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Technique
6.1.3.4 By Application
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Technique
6.1.4.4 By Application
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Technique
6.1.5.4 By Application
6.1.5.5 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Thermo Fisher Scientific Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Minerva Biolabs GmbH
8.3 Charles River Laboratories International
8.4 Gibraltar Laboratories
8.5 Sartorius AG
8.6 Lonza Group Ltd.
8.7 Merck KGaA
8.8 Roche Diagnostics
8.9 SGS S.A.
8.10 American Type Culture Collection
8.11 InvivoGen
8.12 PromoCell GmbH
8.13 Biological Industries Israel Beit Haemek Ltd.
8.14 WuXi AppTec
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
